Century Therapeutics Files 8-K on Financials

Ticker: IPSC · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1850119

Sentiment: neutral

Topics: financial-condition, regulation-fd, financial-statements

TL;DR

Century Therapeutics dropped an 8-K on Jan 13th covering financials. Check it out.

AI Summary

Century Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes disclosures related to Regulation FD and financial statements/exhibits. The company is incorporated in Delaware and headquartered in Philadelphia, PA.

Why It Matters

This 8-K filing provides crucial updates on Century Therapeutics' financial health and operational status, which are important for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a standard 8-K reporting financial information and does not appear to contain any immediately alarming or unusual events.

Key Numbers

Key Players & Entities

FAQ

What specific financial results are being reported in this 8-K?

The filing indicates it covers 'Results of Operations and Financial Condition' but does not detail specific figures within the provided text.

Are there any significant updates regarding Regulation FD disclosures?

The filing explicitly lists 'Regulation FD Disclosure' as an item, suggesting there may be information related to public disclosures.

What type of financial statements and exhibits are included?

The filing states 'Financial Statements and Exhibits' are included, but the specific content of these documents is not detailed in the provided text.

When was the earliest event reported in this filing?

The earliest event reported was on January 13, 2025.

What is Century Therapeutics' principal executive office address?

The principal executive offices are located at 25 North 38th Street, 11th Floor, Philadelphia, Pennsylvania, 19104.

Filing Stats: 795 words · 3 min read · ~3 pages · Grade level 12.1 · Accepted 2025-01-13 07:00:28

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure On January 13, 2025, the Company updated information reflected in a slide presentation, which is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time. The information contained in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit No. Document 99.1 Investor Presentation of Century Therapeutics, Inc., dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CENTURY THERAPEUTICS, INC. By: /s/ Brent Pfeiffenberger, Pharm.D. Name: Brent Pfeiffenberger, Pharm.D. Title: President and Chief Executive Officer Date: January 13, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing